Arch Biopartners Inc. (ACHFF) Research

Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys. This inflammation is a key factor in organ damage or failure, often seen in severe conditions such as sepsis and COVID-19. Additionally, the company is progressing with AB569, an investigational drug aimed at combating or deterring antibiotic-resistant bacterial infections, predominantly through topical application for wounds. Further expanding their portfolio, Arch Biopartners is developing Borg, a peptide-based technology that interfaces with solid surfaces to inhibit biofilm formation and reduce corrosion. Another distinct project is MetaMx, which consists of synthetic molecules specifically engineered to target brain tumor initiating cells and aggressive glioma cells. The company is headquartered in Toronto, Canada.

Open Arch Biopartners Inc. (ACHFF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.